Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eltoprazine
- Development stage
- Phase 2
- Lead developer
- Coeptis Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Eltoprazine is a small molecule drug of the phenylpiperazine class that acts as a serotonergic agent. It functions primarily as an agonist at serotonin 5-HT1A and 5-HT1B receptors and as an antagonist at the serotonin 5-HT2C receptor. Eltoprazine was originally developed for its serenic (anti-aggressive) properties and has been investigated for several neuropsychiatric indications including aggression, attention deficit hyperactivity disorder (ADHD), cognitive disorders, schizophrenia, and levodopa-induced dyskinesia in Parkinson’s disease. The drug was first described in the scientific literature by 1987. Its development history includes work by Solvay (originator), Elto Pharma, and PsychoGenics[1][6]. Recent clinical studies have focused on its potential to reduce levodopa-induced dyskinesias without compromising motor benefits in Parkinson’s disease[4][5][6].
- Other names
- eltoprazine hydrochloride1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperazineEltoprazina
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR1B (5-Hydroxytryptamine Receptor 1B)HTR2C (5-hydroxytryptamine 2C receptor)
Beyond the preview
Go deeper on eltoprazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eltoprazine.